Belzutifan and zanzalintinib for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced kidney cancer (Stage IV) that can't be removed by surgery.
- Your cancer must be the 'clear cell' type (a common form of kidney cancer).
- You can have had up to 3 previous treatments, including no more than 1 type of immunotherapy.
- You cannot need oxygen therapy or have low oxygen levels at rest.
- You must not have serious heart or lung problems, recent blood clots, or active infections like HIV or hepatitis.
- You must have recovered from any major surgery (at least 8 weeks ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
This trial tests new drug combinations for people with advanced kidney cancer whose disease returned after a prior immunotherapy. It's designed to find better treatment options for those who have not received other treatments for advanced disease.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests two drugs (zanzalintinib and MO-03) together to treat advanced kidney cancer that has grown despite previous immunotherapy treatment. The goal is to slow or stop cancer growth in patients who have already tried other treatments.
Hear when a new Carcinoma, Renal Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.